| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
Articles |
Nonadherence to treatment is a common problem in the clinical management of hypercholesterolemic patients. This study was carried out with the aim of monitoring the daily compliance to a 6-month course of lipid-lowering therapy, using a microelectronic device, the Medication Event Monitoring System (MEMS), versus pill count. Forty men with primary hypercholesterolemia were prescribed fluvastatin 1 x 40 mg daily, provided in a MEMS package to record the date and time of each opening of the pillbox. Thirty-nine of 40 patients (98%) completed the study. Total cholesterol and LDL cholesterol levels decreased significantly (18% and 25%, p < 0.001) during the 6-month therapy period. A high mean rate of compliance was achieved by MEMS using the following three indexes--compliance to total prescribed dose (88.8% +/- 13.5%), compliance to prescribed days (82.4% +/- 19.5%), and compliance to prescribed time of day (81.86% +/- 19.5%)--and by pill count (93.4% +/- 9.5%). In addition, the MEMS provided some patterns of nonadherence to medication, undetectable by pill count alone, such as a drug holiday in 38% of cases, a drug omission for more than 7 consecutive days in 9% of cases, and, conversely, use of more than the one prescribed daily dose in 47% of cases. A significant correlation between the rate of compliance and the decrease in LDL cholesterol was observed only when the compliance was assessed by MEMS. The results indicate that MEMS is a useful tool for monitoring compliance in clinical practice and may possibly increase adherence to long-term lipid-lowering therapy.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Menzies, R. Long, A. Trajman, M.-J. Dion, J. Yang, H. Al Jahdali, Z. Memish, K. Khan, M. Gardam, V. Hoeppner, et al. Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection: A Randomized Trial Ann Intern Med, November 18, 2008; 149(10): 689 - 697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Vrijens, E. Tousset, R. Rode, R. Bertz, S. Mayer, and J. Urquhart Successful Projection of the Time Course of Drug Concentration in Plasma During a 1-Year Period From Electronically Compiled Dosing-Time Data Used as Input to Individually Parameterized Pharmacokinetic Models J. Clin. Pharmacol., April 1, 2005; 45(4): 461 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Menzies, M.-J. Dion, B. Rabinovitch, S. Mannix, P. Brassard, and K. Schwartzman Treatment Completion and Costs of a Randomized Trial of Rifampin for 4 Months versus Isoniazid for 9 Months Am. J. Respir. Crit. Care Med., August 15, 2004; 170(4): 445 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Dolder, J. P. Lacro, and D. V. Jeste Adherence to Antipsychotic and Nonpsychiatric Medications in Middle-Aged and Older Patients With Psychotic Disorders Psychosom Med, January 1, 2003; 65(1): 156 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Benner, R. J. Glynn, H. Mogun, P. J. Neumann, M. C. Weinstein, and J. Avorn Long-term Persistence in Use of Statin Therapy in Elderly Patients JAMA, July 24, 2002; 288(4): 455 - 461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Turner and F. M. Hecht Improving on a Coin Toss To Predict Patient Adherence to Medications Ann Intern Med, May 15, 2001; 134(10): 1004 - 1006. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
